arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Moleculin Biotech, Inc.

MBRX

$0.41 ▲ +0.02 (+6.04%) at close

11 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Moleculin Biotech, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -167.3% ↗

FCF / Share $-19.19 ↗

Trailing P/E —

Price / Book 0.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

11-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-33.56M

↓ -28.8% —

FCF / Share Free cash flow per share

$-19.19

↑ +88.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
EPS Growth YoY (%)	85.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-1155.1% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	1.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	-2479.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-28.8% Weak ↓ Weak Declining Year-over-year change in net income	12.5% Fair ↑ Fair Improving Year-over-year change in net income	-2.6% Weak ↑ Weak Improving Year-over-year change in net income	-82.6% Weak ↓ Weak Declining Year-over-year change in net income	8.4% Fair ↑ Fair Improving Year-over-year change in net income	-31.4% Weak ↑ Weak Improving Year-over-year change in net income	-11.2% Weak ↑ Weak Improving Year-over-year change in net income	-21.1% Weak Weak Year-over-year change in net income	-149.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	88.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-1344.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	17.4% Good Good Year-over-year change in free cash flow	-1958.4% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.7% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—
FCF / Net Income (x)	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.19x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	1.31x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.06x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Return on Invested Capital (%)	-167.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-237.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-89.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-46.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-23.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-111.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-110.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-83.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-39.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-20.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-113.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-157.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-77.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-53.4% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-27.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-68.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-69.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-76.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-23.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-223.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1591%)	-232.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1649%)	-114.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-861%)	-55.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-471%)	-20.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-234%)	-97.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-751%)	-84.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-665%)	-83.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-655%)	-57.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-482%)	-26.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-275%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Interest Coverage (x)	—	—	—	—	—	—	-17524.00x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-3005.00x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-2884.33x Weak Weak Operating income divided by interest expense Optimal: > 5x	-90.30x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-8.88M	$-4.28M	$-23.55M	$-43.15M	$-70.90M	$-15.17M	$-10.73M	$-7.13M	$-7.71M	$-5.01M	$0.00

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-28.42	$-189.14	$-15.07	$-15.22	$-0.59	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-19.19	$-173.36	$-12.00	$-14.53	$-0.71	—	—	—	—	—	—
Book Value per Share (USD)	$4.69	$82.93	$11.70	$27.35	$2.94	$1.54	$2.04	$0.50	$0.80	$1.23	$-0.11
Tangible Book Value per Share (USD)	$4.69	$82.93	$11.70	$27.35	$2.94	$1.54	$2.04	$0.50	$0.80	$1.23	$-0.11
Basic Weighted Avg Shares (shares)	1.18M	137,720	1.98M	1.91M	26.88M	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Working Capital (USD)	$2.83M	$-165.00K	$19.46M	$40.78M	$68.88M	$14.28M	$9.91M	$4.10M	$6.09M	$3.88M	$-744.70K
Total Equity (USD)	$15.01M	$11.21M	$26.07M	$52.19M	$78.99M	$17.76M	$15.57M	$14.27M	$17.12M	$14.96M	$-744.70K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	—
Depreciation Expense (USD)	$90.00K	$126.00K	$127.00K	$130.00K	$164.00K	$200.00K	$199.00K	$68.00K	$18.00K	$6.00K	—
Net Income, GAAP (USD)	$-33.56M	$-26.05M	$-29.77M	$-29.02M	$-15.89M	$-17.36M	$-13.21M	$-11.88M	$-9.80M	$-3.93M	—
Operating Cash Flow (USD)	$-22.73M	$-23.86M	$-23.59M	$-27.64M	$-18.95M	$-17.77M	$-17.20M	$-12.20M	$-7.32M	$-3.77M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 44 quarters

Moleculin Biotech, Inc.

Analytical Summary

11-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MBRX with peers